| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
PARIS—Juvisé Pharmaceuticals has announced the successful completion of a transaction with AstraZeneca plc, regarding the acquisition of the commercial rights of two oncology products — Arimidex (anastrozole) and Casodex (bicalutamide) — in a number of European, African and other countries. The medicines have lost their compound patent protection in these countries. AstraZeneca already divested the rights to both Arimidex and Casodex in the U.S. in 2017.
 
Arimidex is an aromatase inhibitor, indicated primarily for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer, and the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
 
Casodex is an androgen-receptor inhibitor, indicated for use in combination therapy with a luteinizing hormone-releasing hormone analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.
 
“We are very pleased to have successfully closed our first deal with AstraZeneca and to enter a therapeutic area with high medical needs such as oncology with Arimidex and Casodex, which are two widely recognized cancer treatments essential for both patients and physicians,” declared Frédéric Mascha, founder and president of Juvisé Pharmaceuticals.
 
This transaction between Juvisé Pharmaceuticals and AstraZeneca is a logical next step after multiple worldwide deals accomplished by Juvisé with several other big pharmaceutical companies over the past years. With this acquisition Juvisé Pharmaceuticals enters the oncology therapeutic area. The company wants to further expand and consolidate its fast-growing ambition.
 
As there were no closing conditions to the divestment, the agreement became effective upon signing. Juvisé Pharmaceuticals has made an upfront payment of $181M to AstraZeneca and may also make future sales-contingent payments of up to $17M. In 2018, Arimidex had sales of $37M in the countries covered by this agreement, and Casodex had sales of $24M. 
 
“Arimidex and Casodex are important established medicines and we are pleased that Juvisé Pharmaceuticals will now take on the work of making sure patients continue to have access to them,” said Dave Fredrickson, executive vice president, Oncology Business Unit, AstraZeneca. “Today’s agreement is part of a broader strategy of reducing our portfolio of mature medicines to reallocate resources towards developing our pipeline of new medicines.”

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Red tumor cells are shown against a teal backdrop showing attachment to tissue.

Decoding the tumor microenvironment with immune profiling

Integrating multiplexed immunohistochemistry with spatial analysis offers a practical way to uncover tumor-immune dynamics.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue